Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Neurobo Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
NRBO
Nasdaq
8731
https://www.neurobopharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Neurobo Pharmaceuticals Inc
NRBO: First Patient Dosed in Phase 1 Trial of DA-1726 for the Treatment of Obesity…
- Apr 23rd, 2024 11:13 am
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
- Apr 17th, 2024 12:05 pm
NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
- Apr 1st, 2024 12:01 pm
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
- Mar 28th, 2024 12:01 pm
NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
- Mar 13th, 2024 12:01 pm
NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer
- Mar 4th, 2024 1:01 pm
NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
- Feb 29th, 2024 1:01 pm
NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference
- Feb 12th, 2024 1:01 pm
NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
- Feb 1st, 2024 1:01 pm
NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
- Jan 18th, 2024 1:01 pm
NRBO: Initiating Coverage of NeuroBo Pharmaceuticals, Inc.; Targeting the $30 Billion+ Obesity Market…
- Jan 18th, 2024 10:17 am
NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement
- Jan 9th, 2024 1:30 pm
NeuroBo to Participate in Industry and Investor Conferences in January
- Jan 2nd, 2024 1:01 pm
NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
- Dec 28th, 2023 1:45 pm
NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split
- Dec 19th, 2023 1:43 pm
Life Science Investor Forum: Presentations Now Available for Online Viewing
- Dec 15th, 2023 1:35 pm
Life Science Investor Forum Agenda Announced for December 14th, 2023
- Dec 12th, 2023 6:02 pm
NeuroBo to Participate in Investor Conferences in December
- Dec 1st, 2023 1:31 pm
NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Nov 13th, 2023 9:05 pm
NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.
- Nov 6th, 2023 1:05 pm
Scroll